# Annexin Pharmaceuticals

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/annexinpharmaceuticals).

## Overview

Annexin Pharmaceuticals AB is a Swedish biopharmaceutical company based in Stockholm that develops ANXV, a recombinant human Annexin A5 protein. The company’s work centers on advancing this drug candidate for vascular injury and inflammation, with additional potential applications in ophthalmology, cancer and other inflammatory diseases. It also holds patents and manufacturing know-how related to the ANXV production process.

## Products & services

• ANXV drug candidate based on recombinant human Annexin A5
• Clinical development in retinal vein occlusion (RVO)
• Preclinical development in oncology and inflammatory diseases
• Patented cell line and GMP manufacturing process for ANXV
• Intellectual property portfolio around Annexin A5 applications

- **Lead drug candidate ANXV** (70%) — The company’s core therapeutic asset is ANXV, a recombinant Annexin A5 protein under clinical development.
- **Clinical development programs** (15%) — Human studies and proof-of-concept work in RVO and related indications.
- **Preclinical pipeline** (10%) — Earlier-stage research in cancer and other inflammatory or vascular diseases.
- **Intellectual property and process know-how** (5%) — Patents, licenses and manufacturing process rights supporting ANXV.

- ANXV recombinant human Annexin A5 drug candidate
- Clinical development for retinal vein occlusion (RVO)
- Preclinical oncology applications for Annexin A5
- Development for vascular inflammation and injury
- Patented GMP manufacturing process and cell line

## Customers

Annexin Pharmaceuticals does not sell a commercialized medicine; its direct counterparties are research sites, clinical investigators, and development partners involved in advancing ANXV. If the program progresses, the eventual customers would be hospitals, specialists and healthcare systems treating vascular, ophthalmic and inflammatory diseases. The company’s value proposition is therefore tied to generating clinical evidence and securing partnering or licensing interest rather than recurring product sales.

- **Clinical research partners** (primary) — Trial sites, investigators and collaborators that help run ANXV proof-of-concept studies.
- **Pharmaceutical licensing partners** (primary) — Biopharma companies that may license ANXV or specific Annexin A5 rights after clinical validation.
- **Ophthalmology treatment market** (secondary) — Specialists and healthcare systems treating retinal vein occlusion and related eye disease.
- **Vascular and inflammatory disease market** (secondary) — Providers treating conditions linked to blood vessel injury and inflammation.
- **Oncology research market** (emerging) — Researchers and future partners evaluating Annexin A5 applications in cancer.

- Clinical trial sites and investigators running ANXV studies
- Potential pharma partners seeking licensing or co-development rights
- Ophthalmology specialists treating retinal vein occlusion
- Hospitals and physicians in vascular and inflammatory disease care
- Future healthcare payers and providers if ANXV reaches market

## Geography

Annexin Pharmaceuticals is headquartered in Stockholm, Sweden and operates as a Swedish public company. Its development work has included clinical activity in the United States, while its intellectual property and manufacturing process are protected in multiple countries. Geography matters because the company’s value depends on cross-border clinical development, patent protection and eventual partnering in larger pharmaceutical markets.

- Headquartered in Stockholm, Sweden
- Swedish public company with local corporate base
- Clinical development has included studies in the United States
- Patent protection and manufacturing rights span multiple countries
- Commercial opportunity is tied to global pharma markets

## Strategy

The company’s strategy is to advance ANXV through proof-of-concept and Phase 2 studies in-house, then use the generated data to support partnerships or licensing deals. It focuses on indications with high unmet medical need, especially retinal vein occlusion and other vascular or inflammatory diseases, while keeping the organization small and development-focused.

- **Advance ANXV clinical development** (short-term) — Clinical data is the main value driver for a development-stage biotech company.
- **Secure partnering or licensing opportunities** (medium-term) — External partners can fund later-stage development and commercialization.
- **Protect intellectual property and manufacturing capability** (long-term) — Patent coverage and process control support differentiation and deal value.

- Advance ANXV through proof-of-concept and Phase 2
- Use clinical data to support partnering and licensing
- Target indications with high unmet medical need
- Build evidence in RVO as a lead indication
- Leverage patents and manufacturing know-how

## Risks

Annexin Pharmaceuticals faces the typical risks of a clinical-stage biotech company: trial failure, uncertain efficacy, safety issues and dependence on external financing. Its concentration in a single lead asset also creates binary development risk, while patent scope, third-party IP and regulatory requirements can affect the path to commercialization.

- **Clinical development failure** [critical] — ANXV’s value depends on positive proof-of-concept and later-stage trial results.
- **Safety or tolerability issues** [high] — Unexpected adverse events could limit dosing, enrollment or indication scope.
- **Intellectual property uncertainty** [high] — The business relies on patents and licensed rights around Annexin A5 and ANXV.
- **Funding dependence** [high] — A development-stage biotech typically consumes cash before product revenue exists.
- **Regulatory and trial execution risk** [medium] — Approvals, site execution and protocol compliance affect timing and cost of studies.

- Clinical trials may fail to show sufficient efficacy
- Safety findings could limit dose or indication expansion
- Single-asset concentration increases binary outcome risk
- Patent disputes or third-party IP could restrict development
- Financing needs are high until partnering or commercialization

## Accounting

As a clinical-stage biotech, the most important accounting judgments are around capitalized development costs, impairment of intangible assets and the valuation of share-based instruments. Reported results can also be affected by the timing of clinical and regulatory spending, while any future partnering arrangements would require careful revenue recognition assessment.

- **Intangible asset and patent impairment** — A negative clinical outcome could trigger impairment charges.
- **Share-based instruments** — Fair value changes can affect equity and reported finance items.
- **Clinical development expense timing** — Quarterly comparability can be distorted by study milestones.
- **Future licensing revenue recognition** — Revenue timing will depend on contract structure and performance obligations.

- Development spending may be expensed or capitalized depending on criteria
- Intangible assets and patents require impairment testing
- Share-based instruments can create valuation and dilution effects
- Clinical trial timing can cause uneven quarterly expenses
- Future licensing income would depend on contract accounting judgments

---

*Last updated: 2026-08-11T04:04:50.880830+00:00*